NO2582728T3 - - Google Patents
Info
- Publication number
- NO2582728T3 NO2582728T3 NO11725095A NO11725095A NO2582728T3 NO 2582728 T3 NO2582728 T3 NO 2582728T3 NO 11725095 A NO11725095 A NO 11725095A NO 11725095 A NO11725095 A NO 11725095A NO 2582728 T3 NO2582728 T3 NO 2582728T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201000529 | 2010-06-15 | ||
| DKPA201100039 | 2011-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2582728T3 true NO2582728T3 (ru) | 2018-01-20 |
Family
ID=44534293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO11725095A NO2582728T3 (ru) | 2010-06-15 | 2011-06-15 |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US9168314B2 (ru) |
| EP (2) | EP3281956A3 (ru) |
| JP (1) | JP6055404B2 (ru) |
| KR (1) | KR101935058B1 (ru) |
| CN (3) | CN106084053B (ru) |
| AU (1) | AU2011267106B2 (ru) |
| BR (1) | BR112012031727B1 (ru) |
| CA (1) | CA2802782C (ru) |
| CY (1) | CY1119616T1 (ru) |
| DK (1) | DK2582728T3 (ru) |
| EA (1) | EA034675B1 (ru) |
| ES (1) | ES2647388T3 (ru) |
| HR (1) | HRP20171789T1 (ru) |
| HU (1) | HUE035599T2 (ru) |
| LT (1) | LT2582728T (ru) |
| ME (1) | ME02919B (ru) |
| MX (1) | MX347893B (ru) |
| NO (1) | NO2582728T3 (ru) |
| NZ (1) | NZ604718A (ru) |
| PL (1) | PL2582728T3 (ru) |
| PT (1) | PT2582728T (ru) |
| RS (1) | RS56599B1 (ru) |
| SI (1) | SI2582728T1 (ru) |
| WO (1) | WO2011157741A2 (ru) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05005160A (es) | 2002-11-15 | 2005-07-22 | Genmab As | Anticuerpos monoclonales humanos contra la cd25. |
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| CN106084053B (zh) * | 2010-06-15 | 2020-01-17 | 根马布股份公司 | 针对组织因子的人抗体药物缀合物 |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| AU2013285355A1 (en) | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
| EP3632462A1 (en) | 2012-07-06 | 2020-04-08 | Genmab B.V. | Dimeric protein with triple mutations |
| EA201500741A1 (ru) | 2013-01-10 | 2016-01-29 | Генмаб Б.В. | ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ |
| CN103342752B (zh) * | 2013-05-16 | 2014-07-09 | 太原博奥特生物技术有限公司 | 一种抗人组织因子单链抗体及其制备方法 |
| KR102372245B1 (ko) * | 2013-11-21 | 2022-03-08 | 젠맵 에이/에스 | 항체-약물 접합체 동결건조 제제 |
| EP3103811A4 (en) * | 2014-02-03 | 2017-11-29 | National Cancer Center | Anti-tissue factor monoclonal antibody |
| AR099812A1 (es) * | 2014-03-21 | 2016-08-17 | Abbvie Inc | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr |
| MX2016012258A (es) * | 2014-04-08 | 2017-01-06 | Seattle Genetics Inc | Dosificacion optima de un conjugado del farmaco del anticuerpo-cd19. |
| CA2929542A1 (en) * | 2015-05-13 | 2016-11-13 | Pfizer Inc. | Treatment with anti-efna4 antibody-drug conjugates |
| EP4180455A1 (en) | 2015-06-29 | 2023-05-17 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| WO2017015582A1 (en) * | 2015-07-22 | 2017-01-26 | Iconic Therapeutics, Inc. | Methods for treating disorders associated with angiogenesis and neovascularization |
| WO2017028823A1 (zh) * | 2015-08-20 | 2017-02-23 | 复旦大学 | 靶向于组织因子的抗体、其制备方法和用途 |
| WO2018036117A1 (zh) * | 2016-08-22 | 2018-03-01 | 复旦大学 | 靶向于组织因子的抗体、其制备方法和用途 |
| DK3347054T3 (da) | 2015-09-11 | 2021-07-19 | Genmab As | Dosisregimer til anti-TF-antistoflægemiddelkonjugater |
| HUE054726T2 (hu) | 2016-03-02 | 2021-09-28 | Eisai R&D Man Co Ltd | Eribulinalapú antitest-gyógyszer konjugátumok és alkalmazási eljárások |
| US11186641B2 (en) * | 2016-03-17 | 2021-11-30 | Oslo Universitetssykehus Hf | Fusion proteins targeting tumour associated macrophages for treating cancer |
| EP3432925A4 (en) | 2016-03-22 | 2019-11-06 | Bionomics Limited | ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY |
| CN106938051B (zh) | 2016-08-22 | 2019-10-11 | 复旦大学 | 靶向于组织因子的抗体-药物偶联物 |
| WO2018083126A1 (en) | 2016-11-01 | 2018-05-11 | Genmab B.V. | Polypeptide variants and uses thereof |
| US20190345186A1 (en) * | 2017-01-24 | 2019-11-14 | Pfizer Inc. | Calicheamicin deratives and antibody drug conjugates thereof |
| US20200181277A1 (en) | 2017-02-10 | 2020-06-11 | Genmab B.V. | Polypeptide variants and uses thereof |
| CN113512111B (zh) * | 2017-03-10 | 2023-08-15 | 北京天广实生物技术股份有限公司 | 抗埃博拉病毒单克隆抗体、其制备方法及用途 |
| US20210177987A1 (en) * | 2017-11-02 | 2021-06-17 | Genmab A/S | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
| JP7165193B2 (ja) * | 2017-11-27 | 2022-11-02 | パーデュー、ファーマ、リミテッド、パートナーシップ | ヒト組織因子を標的とするヒト化抗体 |
| KR20200118029A (ko) * | 2018-01-04 | 2020-10-14 | 아이코닉 테라퓨틱스, 인코포레이티드 | 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법 |
| MA51666A (fr) | 2018-01-24 | 2020-12-02 | Genmab Bv | Variants polypeptidiques et leurs utilisations |
| US20210030888A1 (en) * | 2018-03-07 | 2021-02-04 | Genmab A/S | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
| BR112020017731A2 (pt) * | 2018-03-21 | 2020-12-29 | Genmab A/S | Método para tratar câncer em um indivíduo, estojo, conjugado anticorpo-fármaco, agente à base de platina, e, usos de um conjugado anticorpo-fármaco e de um agente à base de platina |
| WO2019211472A1 (en) | 2018-05-03 | 2019-11-07 | Genmab B.V. | Antibody variant combinations and uses thereof |
| IL307925A (en) | 2018-05-07 | 2023-12-01 | Genmab As | Combination of an antibody against 1-PD and conjugation of a drug with an antibody against TF for use in the treatment of cancer |
| TW202010755A (zh) | 2018-05-07 | 2020-03-16 | 丹麥商珍美寶股份有限公司 | 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法 |
| EP3836950A4 (en) * | 2018-08-16 | 2022-04-06 | Genmab A/S | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER |
| TW202034958A (zh) * | 2018-10-30 | 2020-10-01 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| PE20221004A1 (es) * | 2019-07-03 | 2022-06-15 | Iconic Therapeutics Inc | Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados |
| WO2021089850A1 (en) | 2019-11-06 | 2021-05-14 | Genmab B.V. | Antibody variant combinations and uses thereof |
| TW202131954A (zh) | 2019-11-07 | 2021-09-01 | 丹麥商珍美寶股份有限公司 | 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法 |
| WO2021090272A1 (en) | 2019-11-07 | 2021-05-14 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| AU2020412805A1 (en) * | 2019-12-26 | 2022-07-14 | Hendrix College | Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-CD38 therapeutic agent |
| WO2022002940A1 (en) | 2020-06-29 | 2022-01-06 | Genmab A/S | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
| WO2022056197A1 (en) * | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
| KR20230084508A (ko) | 2020-09-11 | 2023-06-13 | 얀센 바이오테크 인코포레이티드 | 베타 사슬 매개 면역을 조절하기 위한 방법 및 조성물 |
| CA3200974A1 (en) | 2020-11-08 | 2022-05-12 | Seagen Inc. | Combination therapy |
| CN113368232B (zh) * | 2021-06-02 | 2022-08-26 | 上海交通大学 | 多特异性抗原结合蛋白及其应用 |
| CN117730144A (zh) * | 2021-07-29 | 2024-03-19 | 株式会社图尔金 | 具有血液相容性的间充质干细胞、其制备方法及用途 |
| WO2023213960A1 (en) | 2022-05-06 | 2023-11-09 | Genmab A/S | Methods of treating cancer with anti-tissue factor antibody-drug conjugates |
| WO2024083162A1 (en) * | 2022-10-19 | 2024-04-25 | Multitude Therapeutics Inc. | Antibodies, antibody-drug conjugates, preparations and uses thereof |
Family Cites Families (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US505731A (en) | 1893-09-26 | Ice oeeam feeezee | ||
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| CA1319120C (en) | 1985-04-01 | 1993-06-15 | John Henry Kenten | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| US5589173A (en) | 1986-11-04 | 1996-12-31 | Genentech, Inc. | Method and therapeutic compositions for the treatment of myocardial infarction |
| US5223427A (en) * | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
| US5437864A (en) | 1987-03-31 | 1995-08-01 | The Scripps Research Institute | Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| US5879936A (en) | 1988-04-18 | 1999-03-09 | Aluguisse Holding A.G. | Recombinant DNA methods, vectors and host cells |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| WO1989012463A1 (en) | 1988-06-21 | 1989-12-28 | Genentech, Inc. | Method and therapeutic compositions for the treatment of myocardial infarction |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5102990A (en) | 1989-08-09 | 1992-04-07 | Rhomed Incorporated | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| JP3501286B2 (ja) | 1989-12-22 | 2004-03-02 | アプライド リサーチ システムズ，エーアールエス ホールディング ナームロゼ ベノートスハップ | 一定の細胞系又は微生物の内因性遺伝子の発現特徴の変性のための方法 |
| US5891693A (en) | 1990-01-25 | 1999-04-06 | Alusuisse Holdings A.G. | Recombinant DNA methods vectors and host cells |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5506134A (en) | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
| JP3149960B2 (ja) | 1991-01-24 | 2001-03-26 | 財団法人化学及血清療法研究所 | ヒト組織因子を定量する方法 |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| DE69224906T2 (de) | 1991-07-08 | 1998-10-29 | Univ Massachusetts | Thermotropes flüssig-kristallines segment-blockcopolymer |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US6063630A (en) | 1991-11-05 | 2000-05-16 | Transkaryotic Therapies, Inc. | Targeted introduction of DNA into primary or secondary cells and their use for gene therapy |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH05244988A (ja) | 1992-03-04 | 1993-09-24 | Green Cross Corp:The | 抗組織因子モノクローナル抗体、及びこれによる免疫抑制剤 |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1994005328A1 (en) * | 1992-08-28 | 1994-03-17 | The Scripps Research Institute | Inhibition of tumor metastasis via neutralization of tissue factor function |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5879677A (en) | 1992-12-09 | 1999-03-09 | The Scripps Research Institute | Method for inhibition of cerebral tissue factor mediated reperfusion damage |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| EP0804070B1 (en) | 1993-03-09 | 2000-05-24 | Genzyme Corporation | Process of isolation of proteins from milk |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| US5879687A (en) | 1994-04-22 | 1999-03-09 | Corixa Corporation | Methods for enhancement of protective immune responses |
| HU220347B (hu) | 1994-07-11 | 2001-12-28 | Board Of Regents The University Of Texas System | Készítmény az érrendszer specifikus koagulálásához |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
| DK0833911T3 (da) | 1995-06-07 | 2004-08-30 | Ortho Mcneil Pharm Inc | CDR-transplanterede anti-vævsfaktorantistoffer og fremgangsmåder til anvendelse deraf |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| JPH09302000A (ja) | 1996-05-16 | 1997-11-25 | Chemo Sero Therapeut Res Inst | 抗組織因子モノクローナル抗体及び当該モノクローナル抗体を用いた組織因子凝固活性の測定法 |
| US6593291B1 (en) | 1997-02-06 | 2003-07-15 | Entremed, Inc. | Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease |
| US5986065A (en) * | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
| US20040229282A1 (en) | 1997-03-10 | 2004-11-18 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
| US7749498B2 (en) | 1997-03-10 | 2010-07-06 | Genentech, Inc. | Antibodies for inhibiting blood coagulation and methods of use thereof |
| US6719977B1 (en) | 1998-02-12 | 2004-04-13 | The General Hospital Corporation | Methods to potentiate cancer therapies |
| JP2002509716A (ja) | 1998-03-31 | 2002-04-02 | ユニバーシティ テクノロジー コーポレイション | テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物 |
| ES2364266T3 (es) | 1998-04-03 | 2011-08-30 | Chugai Seiyaku Kabushiki Kaisha | Anticuerpo humanizado hacia el factor tisular humano (tf) y procedimiento para construir el anticuerpo humanizado. |
| NZ510488A (en) | 1998-09-04 | 2003-07-25 | Aventis Pasteur | Immunotherapy for HPV DNA-positive cervical cancers with DNA constructs for the administration of HPV antigens to provide an immune response in a host |
| US6387888B1 (en) | 1998-09-30 | 2002-05-14 | American Foundation For Biological Research, Inc. | Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen |
| US6355271B1 (en) | 1999-02-03 | 2002-03-12 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| NZ517372A (en) | 1999-07-29 | 2004-04-30 | Medarex Inc | Human monoclonal antibodies to HER2/neu |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| JP2001213804A (ja) | 2000-01-31 | 2001-08-07 | Chugai Pharmaceut Co Ltd | 抗組織因子抗体の複合体 |
| AU2001250814B2 (en) | 2000-03-16 | 2007-02-15 | Genentech, Inc. | Anti-tissue factor antibodies with enhanced anticoagulant potency |
| WO2002042468A2 (en) | 2000-11-27 | 2002-05-30 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| ATE378403T1 (de) | 2000-11-30 | 2007-11-15 | Medarex Inc | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| WO2002078738A1 (fr) | 2001-03-26 | 2002-10-10 | Koji Suzuki | Agents ameliorant la rheologie sanguine |
| KR20030033007A (ko) | 2001-05-31 | 2003-04-26 | 코울터 파머수티컬, 인코포레이티드 | 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제 |
| US7247304B2 (en) | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
| AU2002332628B2 (en) | 2001-08-23 | 2007-07-26 | Genmab A/S | Human antibodies specific for interleukin 15 (IL-15) |
| DE60232733D1 (de) | 2001-08-30 | 2009-08-06 | Sinai School Medicine | Alternativ gesplicter zirkulierender gewebefaktor |
| CN1575302A (zh) * | 2001-10-02 | 2005-02-02 | 诺沃挪第克公司 | 人组织因子抗体 |
| TWI338009B (en) | 2001-10-29 | 2011-03-01 | Genentech Inc | Antibodies for inhibiting blood coagulation and methods of use thereof |
| JP2005507008A (ja) | 2001-11-02 | 2005-03-10 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | アポトーシスに関連した症状の治療のための、組織因子アゴニストまたは組織因子アンタゴニストの使用 |
| AU2003206571A1 (en) | 2002-02-22 | 2003-09-09 | Prophy Med Ab | Use of an inhibitor or antagonist against tissue factor |
| JP4460443B2 (ja) | 2002-05-01 | 2010-05-12 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 抗凝固剤としての新規組織因子標的化された抗体 |
| US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
| AU2003242506A1 (en) * | 2002-07-12 | 2004-02-02 | Novo Nordisk A/S | Tf antagonist |
| EP2357006B1 (en) | 2002-07-31 | 2015-09-16 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| AU2003277832A1 (en) | 2002-10-31 | 2004-05-25 | Novo Nordisk A/S | Humanized tissue factor antibodies |
| WO2004041302A1 (en) | 2002-11-06 | 2004-05-21 | Novo Nordisk A/S | Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator |
| WO2004041296A2 (en) | 2002-11-06 | 2004-05-21 | Novo Nordisk A/S | Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides |
| AU2003282624A1 (en) | 2002-11-14 | 2004-06-03 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| MXPA05005160A (es) | 2002-11-15 | 2005-07-22 | Genmab As | Anticuerpos monoclonales humanos contra la cd25. |
| EP1590364B1 (en) | 2002-12-16 | 2011-10-05 | Genmab A/S | Human monoclonal antibodies against interleukin 8 (il-8) |
| EP1587549A2 (en) | 2003-01-22 | 2005-10-26 | Novo Nordisk A/S | Radiolabelled tissue factor binding agent and the use thereof |
| US20060034846A1 (en) | 2003-04-14 | 2006-02-16 | Mirella Ezban | Use of TF antagonists |
| US7425328B2 (en) * | 2003-04-22 | 2008-09-16 | Purdue Pharma L.P. | Tissue factor antibodies and uses thereof |
| EP1633309A4 (en) | 2003-05-30 | 2007-06-13 | Centocor Inc | METHOD FOR INHIBITING TUMOR GROWTH WITH ANTI-TISSUE FACTOR ANTIBODIES |
| US7605235B2 (en) * | 2003-05-30 | 2009-10-20 | Centocor, Inc. | Anti-tissue factor antibodies and compositions |
| AU2004251161A1 (en) | 2003-05-30 | 2005-01-06 | Genentech, Inc. | Polypeptides that bind an anti-tissue factor antibody and uses thereof |
| WO2005004793A2 (en) | 2003-06-19 | 2005-01-20 | Tanox Inc. | Compositions and methods for treating coagulation related disorders |
| WO2005025623A2 (en) | 2003-07-28 | 2005-03-24 | Emory University | Ef-24-factor vii conjugates |
| EP1667718A4 (en) | 2003-08-29 | 2007-05-02 | Centocor Inc | METHOD FOR STIMULATING THE SURVIVAL OF A GRAFT WITH ANTI-TISSUE FACTOR ANTIBODY |
| BR122018071968B8 (pt) | 2003-11-06 | 2021-07-27 | Seattle Genetics Inc | conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga |
| US20050191293A1 (en) | 2003-12-10 | 2005-09-01 | Shrikant Deshpande | IP-10 antibodies and their uses |
| EP1744734A2 (en) | 2004-02-20 | 2007-01-24 | Novo Nordisk A/S | Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds |
| WO2005118646A2 (en) | 2004-04-26 | 2005-12-15 | Centocor, Inc. | Epitope directed selection of antibodies to murine tissue factor |
| US8911726B2 (en) | 2004-09-22 | 2014-12-16 | Kyowa Hakko Kirin Co., Ltd | Stabilized human Igg4 antibodies |
| EP1676574A3 (en) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
| US8158590B2 (en) | 2005-08-05 | 2012-04-17 | Syntarga B.V. | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation |
| EP1945264A2 (en) | 2005-10-21 | 2008-07-23 | Genentech, Inc. | Treatment for antiphospholipid-syndrome-related pregnancy complications |
| NZ568762A (en) | 2005-11-07 | 2011-11-25 | Scripps Research Inst | Use of an inhibitor of tissue factor signaling in the manufacture of a medcament for inhibiting or suppressing tissue factor/tissue factor VIIa signaling involving protease activated receptor 2 in a mammal |
| WO2007059782A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| WO2007076091A2 (en) | 2005-12-22 | 2007-07-05 | Genentech, Inc. | Treatment of viral infections using a tissue factor inhibitor |
| RU2489423C2 (ru) | 2006-02-02 | 2013-08-10 | Синтарга Б.В. | Водорастворимые аналоги сс-1065 и их конъюгаты |
| EP2061814B1 (en) * | 2006-10-27 | 2012-06-06 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| WO2008100805A2 (en) * | 2007-02-09 | 2008-08-21 | Genentech, Inc. | Anti-robo4 antibodies and uses therefor |
| CA2685698A1 (en) * | 2007-04-30 | 2008-11-13 | Centocor Ortho Biotech Inc. | Anti-tissue factor antibodies and compositions with enhanced effector function |
| JP6071165B2 (ja) | 2007-05-31 | 2017-02-01 | ゲンマブ エー／エス | 安定なＩｇＧ４抗体 |
| EP2173739B1 (en) | 2007-08-01 | 2013-07-31 | Syntarga B.V. | Substituted cc-1065 analogs and their conjugates |
| EP3255144A1 (en) | 2007-08-10 | 2017-12-13 | E. R. Squibb & Sons, L.L.C. | Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin |
| MX2011004625A (es) | 2008-11-03 | 2011-07-20 | Syntarga Bv | Analogos cc-1065 novedosos y sus conjugados. |
| CN107184976A (zh) * | 2008-11-20 | 2017-09-22 | 弗·哈夫曼-拉罗切有限公司 | 治疗性蛋白质制剂 |
| UA109633C2 (uk) * | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| JP5172811B2 (ja) | 2009-10-27 | 2013-03-27 | 株式会社ジェイエスピー | 発泡性スチレン系樹脂粒子及び該樹脂粒子の製造方法、並びにスチレン系樹脂発泡粒子成形体 |
| CN106084053B (zh) | 2010-06-15 | 2020-01-17 | 根马布股份公司 | 针对组织因子的人抗体药物缀合物 |
| JP5244988B1 (ja) | 2012-02-20 | 2013-07-24 | 浜松ホトニクス株式会社 | 濃度測定装置および濃度測定方法 |
| KR102372245B1 (ko) * | 2013-11-21 | 2022-03-08 | 젠맵 에이/에스 | 항체-약물 접합체 동결건조 제제 |
-
2011
- 2011-06-15 CN CN201610455316.9A patent/CN106084053B/zh active Active
- 2011-06-15 BR BR112012031727-0A patent/BR112012031727B1/pt active IP Right Grant
- 2011-06-15 PT PT117250951T patent/PT2582728T/pt unknown
- 2011-06-15 EP EP17181367.8A patent/EP3281956A3/en active Pending
- 2011-06-15 US US13/704,388 patent/US9168314B2/en active Active
- 2011-06-15 NO NO11725095A patent/NO2582728T3/no unknown
- 2011-06-15 WO PCT/EP2011/059917 patent/WO2011157741A2/en active Application Filing
- 2011-06-15 CN CN202010009498.3A patent/CN111012921A/zh active Pending
- 2011-06-15 NZ NZ604718A patent/NZ604718A/en unknown
- 2011-06-15 RS RS20171169A patent/RS56599B1/sr unknown
- 2011-06-15 CA CA2802782A patent/CA2802782C/en active Active
- 2011-06-15 EA EA201300016A patent/EA034675B1/ru unknown
- 2011-06-15 DK DK11725095.1T patent/DK2582728T3/da active
- 2011-06-15 AU AU2011267106A patent/AU2011267106B2/en active Active
- 2011-06-15 JP JP2013514696A patent/JP6055404B2/ja active Active
- 2011-06-15 ES ES11725095.1T patent/ES2647388T3/es active Active
- 2011-06-15 ME MEP-2017-265A patent/ME02919B/me unknown
- 2011-06-15 CN CN201180039935.5A patent/CN103119065B/zh active Active
- 2011-06-15 EP EP11725095.1A patent/EP2582728B1/en active Active
- 2011-06-15 KR KR1020137000924A patent/KR101935058B1/ko active IP Right Grant
- 2011-06-15 LT LTEP11725095.1T patent/LT2582728T/lt unknown
- 2011-06-15 HU HUE11725095A patent/HUE035599T2/en unknown
- 2011-06-15 MX MX2012014552A patent/MX347893B/es active IP Right Grant
- 2011-06-15 SI SI201131339T patent/SI2582728T1/en unknown
- 2011-06-15 PL PL11725095T patent/PL2582728T3/pl unknown
-
2015
- 2015-09-15 US US14/854,613 patent/US9492565B2/en active Active
-
2016
- 2016-09-27 US US15/277,626 patent/US20170136130A1/en not_active Abandoned
-
2017
- 2017-11-17 HR HRP20171789TT patent/HRP20171789T1/hr unknown
- 2017-11-23 CY CY20171101231T patent/CY1119616T1/el unknown
-
2019
- 2019-03-28 US US16/367,933 patent/US20190315880A1/en not_active Abandoned
-
2021
- 2021-03-10 US US17/198,199 patent/US20210395384A1/en not_active Abandoned